Lantern Pharma Analyst Ratings
Lantern Pharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/10/2023 | 135.55% | EF Hutton | → $11 | Reiterates | Buy → Buy |
| 06/26/2023 | 135.55% | EF Hutton | $11 → $11 | Maintains | Buy |
| 05/25/2023 | 135.55% | EF Hutton | → $11 | Assumes | → Buy |
| 05/18/2023 | — | HC Wainwright & Co. | Initiates Coverage On | → Neutral | |
| 03/21/2023 | 135.55% | EF Hutton | → $11 | Reiterates | → Buy |
| 02/15/2023 | 135.55% | EF Hutton | → $11 | Maintains | Buy |
| 11/01/2022 | 135.55% | EF Hutton | → $11 | Initiates Coverage On | → Buy |
| 03/11/2022 | 670.88% | HC Wainwright & Co. | $34 → $36 | Maintains | Buy |
| 11/02/2021 | 628.05% | HC Wainwright & Co. | $32 → $34 | Maintains | Buy |
| 10/07/2021 | 585.22% | HC Wainwright & Co. | → $32 | Initiates Coverage On | → Buy |
| 07/28/2020 | 413.92% | Colliers Securities | → $24 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/10/2023 | 135.55% | EF Hutton | → 11 美元 | 重申 | 購買 → 購買 |
| 06/26/2023 | 135.55% | EF Hutton | 11 美元 → 11 美元 | 維護 | 購買 |
| 05/25/2023 | 135.55% | EF Hutton | → 11 美元 | 假設 | → 購買 |
| 05/18/2023 | — | HC Wainwright & Co. | 啓動覆蓋開啓 | → 中立 | |
| 03/21/2023 | 135.55% | EF Hutton | → 11 美元 | 重申 | → 購買 |
| 02/15/2023 | 135.55% | EF Hutton | → 11 美元 | 維護 | 購買 |
| 11/01/2022 | 135.55% | EF Hutton | → 11 美元 | 啓動覆蓋開啓 | → 購買 |
| 03/11/2022 | 670.88% | HC Wainwright & Co. | 34 美元 → 36 美元 | 維護 | 購買 |
| 11/02/2021 | 628.05% | HC Wainwright & Co. | 32 美元 → 34 美元 | 維護 | 購買 |
| 2021 年 7 月 10 日 | 585.22% | HC Wainwright & Co. | → 32 美元 | 啓動覆蓋開啓 | → 購買 |
| 2020 年 7 月 28 日 | 413.92% | 高力證券 | → 24 美元 | 啓動覆蓋開啓 | → 購買 |
What is the target price for Lantern Pharma (LTRN)?
Lantern Pharma（LTRN）的目標價格是多少？
The latest price target for Lantern Pharma (NASDAQ: LTRN) was reported by EF Hutton on August 10, 2023. The analyst firm set a price target for $11.00 expecting LTRN to rise to within 12 months (a possible 135.55% upside). 7 analyst firms have reported ratings in the last year.
EF Hutton於2023年8月10日公佈了Lantern Pharma（納斯達克股票代碼：LTRN）的最新目標股價。這家分析公司將目標股價定爲11.00美元，預計LTRN將在12個月內升至12個月內（可能上漲135.55％）。去年有7家分析公司公佈了評級。
What is the most recent analyst rating for Lantern Pharma (LTRN)?
分析師對Lantern Pharma（LTRN）的最新評級是多少？
The latest analyst rating for Lantern Pharma (NASDAQ: LTRN) was provided by EF Hutton, and Lantern Pharma reiterated their buy rating.
Lantern Pharma（納斯達克股票代碼：LTRN）的最新分析師評級由EF Hutton提供，Lantern Pharma重申了他們的買入評級。
When is the next analyst rating going to be posted or updated for Lantern Pharma (LTRN)?
Lantern Pharma（LTRN）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lantern Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lantern Pharma was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.
分析師在進行了廣泛的研究（包括瀏覽公開財務報表、與Lantern Pharma的高管和客戶交談以及聽取業績電話會議）後得出了股票評級。大多數分析師每三個月進行一次評級，因此每家公司每年應該獲得4個評級。Lantern Pharma的最新評級是在2023年8月10日提交的，因此您應該預計下一個評級將在2024年8月10日左右公佈。
Is the Analyst Rating Lantern Pharma (LTRN) correct?
分析師對Lantern Pharma（LTRN）的評級正確嗎？
While ratings are subjective and will change, the latest Lantern Pharma (LTRN) rating was a reiterated with a price target of $0.00 to $11.00. The current price Lantern Pharma (LTRN) is trading at is $4.67, which is within the analyst's predicted range.
儘管評級是主觀的，將會發生變化，但最新的Lantern Pharma（LTRN）評級得到了重申，目標股價爲0.00美元至11.00美元。Lantern Pharma（LTRN）目前的交易價格爲4.67美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。